At the American Society of Clinical Oncology 2025 Genitourinary Cancers Symposium, updated results of the single-arm phase II RC48-C017 trial were presented, which evaluated the efficacy and safety of neoadjuvant disitamab vedotin (DV) with perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression. Data from the study’s post hoc event-free survival (EFS) analysis were also presented. ...
Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
The interim analysis of the RETAIN-2 trial demonstrated a 46% pT0 rate among those undergoing cystectomy.
Nivolumab demonstrated sustained DFS benefits across all patients with MIBC and in prior NAC subgroups.
Dr. Geynisman shares insights on the feasibility of bladder-sparing approaches in treating muscle-invasive bladder cancer.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.